


Pharmaceuticals & Biotechnology | Small Cap
Dishman Carbogen Amcis Ltd, operating in the Healthcare Services sector, demonstrates a mixed financial performance. The company shows strong solvency and growth, indicating a solid foundation and expansion in key areas. However, liquidity and efficiency are areas of concern, suggesting challenges in managing short-term obligations and asset utilization. Profitability metrics are also varied, with some positive gross and operating margins offset by negative returns on equity and net margins. The company's coverage ratios are weak, indicating potential difficulties in meeting its interest obligations. Overall, while the company exhibits growth potential and financial stability, it needs to address its liquidity and efficiency challenges to ensure sustained financial health. It's important to consider the unique dynamics of the Healthcare Services industry, which can significantly impact financial ratios.
Dishman Carbogen Amcis Ltd, operating in the Healthcare Services sector, demonstrates a mixed financial performance. The company shows strong solvency and growth, indicating a solid foundation and expansion in key areas. However, liquidity and efficiency are areas of concern, suggesting challenges in managing short-term obligations and asset utilization. Profitability metrics are also varied, with some positive gross and operating margins offset by negative returns on equity and net margins. The company's coverage ratios are weak, indicating potential difficulties in meeting its interest obligations. Overall, while the company exhibits growth potential and financial stability, it needs to address its liquidity and efficiency challenges to ensure sustained financial health. It's important to consider the unique dynamics of the Healthcare Services industry, which can significantly impact financial ratios.
Overall Valuation Score
Markets Depth NSE
Buy Orders
Bid
Quantity
Orders
No buy depth
Total
0
0
Sell Orders
Ask
Quantity
Orders
No sell depth
Total
0
0
Markets Today NSE
High
0.00
Low
0.00
Open
0.00
Close
0.00
Prev Close
0.00
Avg Price
0.00
Volume
0
Last Traded Quantity
0
Last Traded Time
N/A
Price Movement Indicator
Today's Low: 0.00
Today's High: 0.00
P/E RATIO (TTM)
-79.45
Industry Median
30.92
Small Cap Median
28.82
P/E RATIO
31.30
P/B RATIO
0.46
Industry Median
3.39
Small Cap Median
2.92
P/S RATIO
1.04
Industry Median
3.36
Small Cap Median
2.72
Others
PEG RATIO
0.00
EV/EBITDA RATIO
6.30
The Calculations Shown Above Are Based on the Last Traded Price (LTP) of ₹194.66 as on Aug 6, 2026.
The growth ratios paint a promising picture of the company's expansion. The company has a strong growth position. This growth momentum positions the company favorably for future success. On the other hand, the company needs to sustain its growth position.
| Growth Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue Growth Rate | 11.98 | 12.7 | 8.41 | 3.67 | 8.11 |
| Operating Profit Growth Rate | 20.8 | 0.3 | -13.86 | 63.99 | 20.68 |
| Earnings Per Share (EPS) Growth | -110.92 | -265.22 | 415.26 | -102.15 | 2861.9 |
| Asset Growth Rate | 3.33 | 9.32 | 1.4 | 4.35 | 19.39 |
| Net Income Growth Rate | -110.91 | -266.67 | 410 | -101.96 | 3133.33 |
Revenue Growth Rate
Operating Profit Growth Rate
Earnings Per Share (EPS) Growth
Asset Growth Rate
Net Income Growth Rate
Peer Comparison empowers investors to evaluate a company against its industry peers using key financial metrics like P/E ratio, EPS, and profit margins. It helps identify whether a company is overvalued, undervalued, or performing in line with competitors. Investors can use this data to spot opportunities, assess risks, and make informed decisions. This contextual view adds depth beyond standalone company analysis.
| NO | Company Name | Health Score | P/E Ratio | Valuation | OPM | EPS | Latest Profit & Loss |
|---|---|---|---|---|---|---|---|
| 1 | Amrutanjan Health Care Ltd | 8.25 | 73.76 | Highly Overvalued | 31.00 | 20.03 | 21.00 |
| 2 | Windlas Biotech Ltd | 7.52 | 27.76 | Neutral | 105.00 | 32.19 | 66.00 |
| 3 | Innova Captab Ltd | 7.36 | 38.74 | Overvalued | 243.00 | 14.63 | 141.00 |
| 4 | Aarti Drugs Ltd | 7.20 | 19.23 | Undervalued | 309.00 | 18.54 | 195.00 |
| 5 | Hikal Ltd | 7.13 | -55.92 | Neutral | 220.00 | -3.95 | -49.00 |
| 6 | RPG Life Sciences Ltd | 7.12 | 38.61 | Neutral | 147.00 | 69.64 | 115.00 |
| 7 | Morepen Laboratories Ltd | 7.12 | 45.91 | Neutral | 126.00 | 1.21 | 96.00 |
| 8 | Alembic Ltd | 7.06 | 7.01 | Undervalued | 90.00 | 4.85 | 317.00 |
| 9 | SMS Pharmaceuticals Ltd | 5.94 | 32.80 | Neutral | 171.00 | 9.35 | 102.00 |
| 10 | Gufic BioSciences Ltd | 5.49 | 63.18 | Neutral | 151.00 | 6.30 | 64.00 |
| 11 | Dishman Carbogen Amcis Ltd | 5.38 | 31.30 | Neutral | 566.00 | -2.45 | 97.00 |
| 12 | IOL Chemicals & Pharmaceuticals Ltd | 5.31 | 34.79 | Undervalued | 269.00 | 4.69 | 138.00 |
| 13 | Indoco Remedies Ltd | 5.26 | -21.52 | Neutral | 142.00 | -0.61 | -99.00 |
| 14 | Orchid Pharma Ltd | 4.85 | 246.31 | Neutral | 41.00 | 8.91 | 21.00 |
| 15 | Sequent Scientific Ltd | 4.61 | 313.39 | Overvalued | 162.00 | 1.74 | 32.00 |
| 16 | Sun Pharma Advanced Research Company Ltd | 4.35 | 4.53 | Neutral | 1599.00 | 47.83 | 1553.00 |
| 17 | Solara Active Pharma Sciences Ltd | 4.34 | -249.32 | Neutral | 187.00 | -1.50 | -7.00 |
| 18 | Zota Health Care Ltd | 3.97 | -58.38 | Neutral | 19.00 | 8.06 | -74.00 |
0 Credits RemainingUnlock Deep Technical Insights in Seconds Only with Dhanarthi AI
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 1 Hour Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral